627 related articles for article (PubMed ID: 17768272)
1. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
Ray LA; Bujarski S; Chin PF; Miotto K
Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
[TBL] [Abstract][Full Text] [Related]
3. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
[TBL] [Abstract][Full Text] [Related]
4. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
5. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
[TBL] [Abstract][Full Text] [Related]
6. The μ-opioid receptor and treatment response to naltrexone.
Thorsell A
Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
[TBL] [Abstract][Full Text] [Related]
8. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
Setiawan E; Pihl RO; Benkelfat C; Leyton M
Pharmacogenomics; 2012 Jul; 13(10):1161-72. PubMed ID: 22909206
[TBL] [Abstract][Full Text] [Related]
9. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
[TBL] [Abstract][Full Text] [Related]
10. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Kranzler HR; Armeli S; Covault J; Tennen H
Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
12. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
15. Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.
Bujarski S; MacKillop J; Ray LA
Exp Clin Psychopharmacol; 2012 Jun; 20(3):181-90. PubMed ID: 22429255
[TBL] [Abstract][Full Text] [Related]
16. The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype.
Setiawan E; Pihl RO; Cox SM; Gianoulakis C; Palmour RM; Benkelfat C; Leyton M
Alcohol Clin Exp Res; 2011 Jun; 35(6):1134-41. PubMed ID: 21410481
[TBL] [Abstract][Full Text] [Related]
17. Stress-induced and cue-induced craving for alcohol in heavy drinkers: Preliminary evidence of genetic moderation by the OPRM1 and CRH-BP genes.
Ray LA
Alcohol Clin Exp Res; 2011 Jan; 35(1):166-74. PubMed ID: 21039637
[TBL] [Abstract][Full Text] [Related]
18. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking.
Krishnan-Sarin S; Krystal JH; Shi J; Pittman B; O'Malley SS
Biol Psychiatry; 2007 Sep; 62(6):694-7. PubMed ID: 17336941
[TBL] [Abstract][Full Text] [Related]
19. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers.
van den Wildenberg E; Wiers RW; Dessers J; Janssen RG; Lambrichs EH; Smeets HJ; van Breukelen GJ
Alcohol Clin Exp Res; 2007 Jan; 31(1):1-10. PubMed ID: 17207095
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
Haile CN; Kosten TA; Kosten TR
Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
